Drugs / NVG-2089
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07095127 | Sep 2025 → Jun 2027 expected | thrombocytopenia due to immune destruction | Nuvig Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07027111 | Apr 2025 → Jul 2026 overdue | polyneuropathy, inflammatory demyelinating, chronic | Nuvig Therapeutics, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-05-14 | Nuvig Therapeutics, Inc. | Results Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data nuvigtx.com ↗
Phase 1 data show NVG-2089 was well tolerated with no serious or severe adverse events, supporting advancement into Phase 2 development for CIDP |
| 2024-02-12 | Nuvig Therapeutics, Inc. | Regulatory Nuvig Initiates Clinical Development of Next-Generation Immune Modulator NVG-2089 nuvigtx.com ↗
Nuvig also announced that the FDA granted fast track designation (FTD) for NVG-2089’s development in bullous pemphigoid. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-05-14 | Nuvig Therapeutics, Inc. | Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data nuvigtx.com ↗ |
| 2024-02-12 | Nuvig Therapeutics, Inc. | Nuvig Initiates Clinical Development of Next-Generation Immune Modulator NVG-2089 nuvigtx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NVG-2089 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07095127 ↗ |
| Route | Intravenous | “Intravenous NVG-2089” NCT07027111 ↗ |